OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
When three is not a crowd: trispecific antibodies for enhanced cancer immunotherapy
Antonio Tapia‐Galisteo, Marta Compte, Luís Álvarez-Vallina, et al.
Theranostics (2023) Vol. 13, Iss. 3, pp. 1028-1041
Open Access | Times Cited: 45
Antonio Tapia‐Galisteo, Marta Compte, Luís Álvarez-Vallina, et al.
Theranostics (2023) Vol. 13, Iss. 3, pp. 1028-1041
Open Access | Times Cited: 45
Showing 1-25 of 45 citing articles:
The present and future of bispecific antibodies for cancer therapy
Christian Klein, Ulrich Brinkmann, Janice M. Reichert, et al.
Nature Reviews Drug Discovery (2024) Vol. 23, Iss. 4, pp. 301-319
Closed Access | Times Cited: 131
Christian Klein, Ulrich Brinkmann, Janice M. Reichert, et al.
Nature Reviews Drug Discovery (2024) Vol. 23, Iss. 4, pp. 301-319
Closed Access | Times Cited: 131
Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies
Antonio Tapia‐Galisteo, Luis Álvarez‐Vallina, Laura Sanz
Journal of Hematology & Oncology (2023) Vol. 16, Iss. 1
Open Access | Times Cited: 56
Antonio Tapia‐Galisteo, Luis Álvarez‐Vallina, Laura Sanz
Journal of Hematology & Oncology (2023) Vol. 16, Iss. 1
Open Access | Times Cited: 56
The Evolving Landscape of Antibody–Drug Conjugates: In Depth Analysis of Recent Research Progress
Janet M. Sasso, Rumiana Tenchov, Robert E. Bird, et al.
Bioconjugate Chemistry (2023) Vol. 34, Iss. 11, pp. 1951-2000
Open Access | Times Cited: 55
Janet M. Sasso, Rumiana Tenchov, Robert E. Bird, et al.
Bioconjugate Chemistry (2023) Vol. 34, Iss. 11, pp. 1951-2000
Open Access | Times Cited: 55
Bispecific and multispecific antibodies in oncology: opportunities and challenges
Maria-Elisabeth Goebeler, Gernot Stuhler, Ralf C. Bargou
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 7, pp. 539-560
Closed Access | Times Cited: 37
Maria-Elisabeth Goebeler, Gernot Stuhler, Ralf C. Bargou
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 7, pp. 539-560
Closed Access | Times Cited: 37
Claudin 18.2 as a New Biomarker in Gastric Cancer—What Should We Know?
Maria Cecília Mathias-Machado, Victor Hugo Fonseca de Jesus, Alexandre A. Jácome, et al.
Cancers (2024) Vol. 16, Iss. 3, pp. 679-679
Open Access | Times Cited: 11
Maria Cecília Mathias-Machado, Victor Hugo Fonseca de Jesus, Alexandre A. Jácome, et al.
Cancers (2024) Vol. 16, Iss. 3, pp. 679-679
Open Access | Times Cited: 11
Mechanisms for resistance to BCMA-targeted immunotherapies in multiple myeloma
Tingting Yue, Yue Sun, Yun Dai, et al.
Blood Reviews (2025), pp. 101256-101256
Closed Access | Times Cited: 1
Tingting Yue, Yue Sun, Yun Dai, et al.
Blood Reviews (2025), pp. 101256-101256
Closed Access | Times Cited: 1
Whole-canine neutralizing antibodies generated by single B cell antibody technology elicit therapeutic protection against canine distemper virus infection
Pengfei Shi, Zhihao Wang, Wei Sheng, et al.
Veterinary Microbiology (2025), pp. 110412-110412
Closed Access | Times Cited: 1
Pengfei Shi, Zhihao Wang, Wei Sheng, et al.
Veterinary Microbiology (2025), pp. 110412-110412
Closed Access | Times Cited: 1
Tri-specific tribodies targeting 5T4, CD3, and immune checkpoint drive stronger functional T-cell responses than combinations of antibody therapeutics
Margherita Passariello, Lorenzo Manna, Rosa Rapuano Lembo, et al.
Cell Death Discovery (2025) Vol. 11, Iss. 1
Open Access | Times Cited: 1
Margherita Passariello, Lorenzo Manna, Rosa Rapuano Lembo, et al.
Cell Death Discovery (2025) Vol. 11, Iss. 1
Open Access | Times Cited: 1
Current Landscape and Future Directions in Cancer Immunotherapy: Therapies, Trials, and Challenges
S. A. Tilakaratne Bandara, Sreejith Raveendran
Cancers (2025) Vol. 17, Iss. 5, pp. 821-821
Open Access | Times Cited: 1
S. A. Tilakaratne Bandara, Sreejith Raveendran
Cancers (2025) Vol. 17, Iss. 5, pp. 821-821
Open Access | Times Cited: 1
Metabolic adaptations determine whether natural killer cells fail or thrive within the tumor microenvironment
Adnan Moinuddin, Sophie M. Poznanski, Ana L. Portillo, et al.
Immunological Reviews (2024) Vol. 323, Iss. 1, pp. 19-39
Closed Access | Times Cited: 8
Adnan Moinuddin, Sophie M. Poznanski, Ana L. Portillo, et al.
Immunological Reviews (2024) Vol. 323, Iss. 1, pp. 19-39
Closed Access | Times Cited: 8
Revolutionizing cancer immunotherapy: unleashing the potential of bispecific antibodies for targeted treatment
Xiaohan Guo, Yi Wu, Xue Ying, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 14
Xiaohan Guo, Yi Wu, Xue Ying, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 14
Trispecific antibodies for cancer immunotherapy
Yin Yao, Yiyin Hu, Fei Wang
Immunology (2023) Vol. 169, Iss. 4, pp. 389-399
Open Access | Times Cited: 13
Yin Yao, Yiyin Hu, Fei Wang
Immunology (2023) Vol. 169, Iss. 4, pp. 389-399
Open Access | Times Cited: 13
Bispecific Antibodies and Autologous Chimeric Antigen Receptor T cell therapies for Treatment of Hematological Malignancies
Samer Al Hadidi, Helen E. Heslop, Malcolm K. Brenner, et al.
Molecular Therapy (2024) Vol. 32, Iss. 8, pp. 2444-2460
Closed Access | Times Cited: 5
Samer Al Hadidi, Helen E. Heslop, Malcolm K. Brenner, et al.
Molecular Therapy (2024) Vol. 32, Iss. 8, pp. 2444-2460
Closed Access | Times Cited: 5
Orchestrating NK and T cells via tri-specific nano-antibodies for synergistic antitumor immunity
Qian‐Ni Ye, Long Zhu, Jie Liang, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 5
Qian‐Ni Ye, Long Zhu, Jie Liang, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 5
Next-Generation Therapeutic Antibodies for Cancer Treatment: Advancements, Applications, and Challenges
A. Raja, Abhishek Kasana, Vaishali Verma
Molecular Biotechnology (2024)
Closed Access | Times Cited: 5
A. Raja, Abhishek Kasana, Vaishali Verma
Molecular Biotechnology (2024)
Closed Access | Times Cited: 5
Natural killer cell engagers: From bi‐specific to tri‐specific and tetra‐specific engagers for enhanced cancer immunotherapy
An Zhu, Yu Bai, Yanyang Nan, et al.
Clinical and Translational Medicine (2024) Vol. 14, Iss. 11
Open Access | Times Cited: 5
An Zhu, Yu Bai, Yanyang Nan, et al.
Clinical and Translational Medicine (2024) Vol. 14, Iss. 11
Open Access | Times Cited: 5
Monoclonal antibodies: From magic bullet to precision weapon
Hassan Aboul-Ella, Asmaa Gohar, Aya Ahmed Ali, et al.
Molecular Biomedicine (2024) Vol. 5, Iss. 1
Open Access | Times Cited: 4
Hassan Aboul-Ella, Asmaa Gohar, Aya Ahmed Ali, et al.
Molecular Biomedicine (2024) Vol. 5, Iss. 1
Open Access | Times Cited: 4
“Innate Immune Cell Engagers: Matchmakers for Next-Generation Immunotherapy”
Sascha Cording, Jens Pahl, Kristina Ellwanger, et al.
Springer eBooks (2025), pp. 1-25
Closed Access
Sascha Cording, Jens Pahl, Kristina Ellwanger, et al.
Springer eBooks (2025), pp. 1-25
Closed Access
Two Are Better than One: The Bi-Specific Antibody Mosunetuzumab Reveals an Improved Immune Response of Vγ9Vδ2 T Cells Targeting CD20 in Malignant B Cells in Comparison to the Mono-Specific Antibody Obinutuzumab
Lothar Marischen, Jürgen Fritsch, Jovana Ilic, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 3, pp. 1262-1262
Open Access
Lothar Marischen, Jürgen Fritsch, Jovana Ilic, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 3, pp. 1262-1262
Open Access
Quantifying antibody binding: techniques and therapeutic implications
James Lodge, Lewis Kajtar, R. E. Duxbury, et al.
mAbs (2025) Vol. 17, Iss. 1
Open Access
James Lodge, Lewis Kajtar, R. E. Duxbury, et al.
mAbs (2025) Vol. 17, Iss. 1
Open Access
Multispecific Antibodies Targeting PD-1/PD-L1 in Cancer
Miaomiao Chen, Yuli Zhou, Kelvin K H Bao, et al.
BioDrugs (2025)
Closed Access
Miaomiao Chen, Yuli Zhou, Kelvin K H Bao, et al.
BioDrugs (2025)
Closed Access
Enzyme-Instructed Self-assembled Supramolecular Bi-Antibodies for Inhibition and Imaging of Atherosclerosis Progression
Shuang Bian, Yanyan Zhu, Ninglin Zhao, et al.
Materials Today Bio (2025), pp. 101827-101827
Open Access
Shuang Bian, Yanyan Zhu, Ninglin Zhao, et al.
Materials Today Bio (2025), pp. 101827-101827
Open Access
Antibody-drug conjugates in cancer therapy: innovations, challenges, and future directions
Shivangi Kumari, Sonam Raj, M. Arockia Babu, et al.
Archives of Pharmacal Research (2023) Vol. 47, Iss. 1, pp. 40-65
Closed Access | Times Cited: 10
Shivangi Kumari, Sonam Raj, M. Arockia Babu, et al.
Archives of Pharmacal Research (2023) Vol. 47, Iss. 1, pp. 40-65
Closed Access | Times Cited: 10
Fumarate Hydratase Enhances the Therapeutic Effect of PD-1 Antibody in Colorectal Cancer by Regulating PCSK9
Le Qin, Liang Shi, Yu Wang, et al.
Cancers (2024) Vol. 16, Iss. 4, pp. 713-713
Open Access | Times Cited: 3
Le Qin, Liang Shi, Yu Wang, et al.
Cancers (2024) Vol. 16, Iss. 4, pp. 713-713
Open Access | Times Cited: 3
Developability considerations for bispecific and multispecific antibodies
Alaa Amash, Gesa Volkers, Patrick Farber, et al.
mAbs (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 3
Alaa Amash, Gesa Volkers, Patrick Farber, et al.
mAbs (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 3
